Un-Audited Financial Result for the Quarter ended on 31.12.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.1 pts more than Nifty Microcap 250 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Zenith Healthcare's board approved unaudited Q3 FY26 results on February 12, 2026, reviewed by statutory auditor Doshi Doshi & Co with a clean limited-review report. Revenue from operations for Q3 FY26 rose to ₹248.30 lacs from ₹230.52 lacs in Q3 FY25, a 7.7% YoY gain. Profit before tax swung to ₹24.68 lacs versus a loss of ₹10.78 lacs a year ago, and net profit came in at ₹22.41 lacs against a loss of ₹29.22 lacs in Q3 FY25. For the nine-month period, revenue was nearly flat at ₹790.07 lacs (vs ₹790.44 lacs), but net profit turned around sharply to ₹34.71 lacs from a loss of ₹4.27 lacs. EPS for Q3 stood at ₹0.042 versus minus ₹0.05 in the year-ago quarter. The company operates in a single segment — pharmaceuticals trading — and is a small-cap entity with paid-up equity of about ₹5.37 crore.
The sharp swing from loss to profit, driven primarily by lower raw material and other expenses, is a clear positive signal for shareholders and could lift sentiment on this thinly-traded stock. However, top-line growth remains anemic and full-year FY26 profitability will need to be sustained in Q4 to confirm a genuine turnaround.